Filters

Rebecca E Wrishko, Jacqueline B McCrea, Ka Lai Yee, Wen Liu, Deborah Panebianco, Eric Mangin, Manu Chakravarthy, Maria P Martinez-Cantarin, Walter K Kraft

Clinical drug investigation 2019;39(5):441-451

Free Full Text

Abstract

Evaluation of CYP3A-mediated drug-drug interactions with romidepsin in patients with advanced cancer.

Eric Laille, Manish Patel, Suzanne F Jones, Howard A Burris, Jeffrey Infante, Charlotte Lemech, Liangang Liu, Hendrik-Tobias Arkenau

Journal of clinical pharmacology 2016;55(12):1378-85

Free Full Text

Abstract

The effects of ketoconazole and rifampin on the single-dose pharmacokinetics of crizotinib in healthy subjects.

Huiping Xu, Melissa O'Gorman, Weiwei Tan, Nicoletta Brega, Akintunde Bello

European journal of clinical pharmacology 2016;71(12):1441-9

Full Text

Abstract

Effects of CYP3A4 Inhibitors Ketoconazole and Verapamil and the CYP3A4 Inducer Rifampicin on the Pharmacokinetic Parameters of Fostamatinib: Results from In Vitro and Phase I Clinical Studies.

Kelli Craven, Tim Mant, David Sweeny, Muhammad Baluom, Elliott B Grossbard, Clive Brealey, Stuart Oliver, David Lau, Michael Gillen, David Millson, Paul Martin

Drugs in R&D 2016;16(1):81-92

Free Full Text

Abstract

Evaluation of Cytochrome P450 (CYP) 3A4-Based Interactions of Levomilnacipran with Ketoconazole, Carbamazepine or Alprazolam in Healthy Subjects.

Laishun Chen, Nayra Gad, William M Greenberg, Julie Wangsa, Antonia Periclou, Parviz Ghahramani, Ramesh Boinpally

Clinical drug investigation 2016;35(10):601-12

Full Text

Abstract

Exploratory effects of a strong CYP3A inhibitor (ketoconazole), a strong CYP3A inducer (rifampicin), and concomitant ethanol on piragliatin pharmacokinetics and pharmacodynamics in type 2 diabetic patients.

Jianguo Zhi, Suoping Zhai, Angela Georgy, Zhenming Liang, Mark Boldrin

Journal of clinical pharmacology 2017;56(5):548-54

Full Text

Abstract

Principi di farmacodinamica e farmacocinetica nello switch tra antipsicotici: focus su cariprazina.

Arianna Goracci, Alessandro Cuomo, Bruno Beccarini Crescenzi, Simone Bolognesi, Andrea Fagiolini

Rivista di psichiatria 2020;54(6):1-6

Full Text

Abstract

Influence of CYP3A4 induction/inhibition on the pharmacokinetics of vilazodone in healthy subjects.

Antonia Periclou, Samir Gupta, Nayra Gad, Ramesh Boinpally

Clinical therapeutics 2016;36(11):1638-49

Full Text

Abstract

Results: 1 – 15 / 28

Filters

Expert Opinion

Text Availability

Publication Types

Publication Year

Results for ""Cytochrome P-450 CYP3A Inducers""[mesh_terms]

An Exposure-Response Modeling Approach to Examine the Relationship Between Potency of CYP3A Inducer and Plasma 4β-Hydroxycholesterol in Healthy Subjects.

Quinine compared to 4β-hydroxycholesterol and midazolam as markers for CYP3A induction by rifampicin.

Prescriptions of CYP3A4- and P-gp inducers for patients on direct oral anticoagulants: Bridging the gap between epidemiology and patient management for optimal thromboembolic event prevention.

Pharmacokinetic Interaction of Rifampicin with Oral Versus Intravenous Anticancer Drugs: Challenges, Dilemmas and Paradoxical Effects Due to Multiple Mechanisms.

Perspective: 4β-hydroxycholesterol as an emerging endogenous biomarker of hepatic CYP3A.

Identification of the caffeine to trimethyluric acid ratio as a dietary biomarker to characterise variability in cytochrome P450 3A activity.

Comparison of two endogenous biomarkers of CYP3A4 activity in a drug-drug interaction study between midostaurin and rifampicin.

Effect of CYP3A Inhibition and Induction on the Pharmacokinetics of Suvorexant: Two Phase I, Open-Label, Fixed-Sequence Trials in Healthy Subjects.

Evaluation of CYP3A-mediated drug-drug interactions with romidepsin in patients with advanced cancer.

The effects of ketoconazole and rifampin on the single-dose pharmacokinetics of crizotinib in healthy subjects.

Effects of CYP3A4 Inhibitors Ketoconazole and Verapamil and the CYP3A4 Inducer Rifampicin on the Pharmacokinetic Parameters of Fostamatinib: Results from In Vitro and Phase I Clinical Studies.

Evaluation of Cytochrome P450 (CYP) 3A4-Based Interactions of Levomilnacipran with Ketoconazole, Carbamazepine or Alprazolam in Healthy Subjects.

Exploratory effects of a strong CYP3A inhibitor (ketoconazole), a strong CYP3A inducer (rifampicin), and concomitant ethanol on piragliatin pharmacokinetics and pharmacodynamics in type 2 diabetic patients.

Principi di farmacodinamica e farmacocinetica nello switch tra antipsicotici: focus su cariprazina.

Influence of CYP3A4 induction/inhibition on the pharmacokinetics of vilazodone in healthy subjects.

Results for
""Cytochrome P-450 CYP3A Inducers""[mesh_terms]